Verastem Company Profile (NASDAQ:VSTM)

About Verastem (NASDAQ:VSTM)

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VSTM
  • CUSIP: 92337C10
  • Web:
  • Market Cap: $146.12 million
  • Outstanding Shares: 36,992,000
Average Prices:
  • 50 Day Moving Avg: $4.72
  • 200 Day Moving Avg: $3.17
  • 52 Week Range: $1.05 - $5.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.56
  • P/E Growth: -1.89
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.30 per share
  • Price / Book: 3.04
  • EBITDA: ($45,870,000.00)
  • Return on Equity: -69.88%
  • Return on Assets: -59.24%
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 5.40%
  • Quick Ratio: 5.40%
  • Average Volume: 1.23 million shs.
  • Beta: 2.29
  • Short Ratio: 1.47

Frequently Asked Questions for Verastem (NASDAQ:VSTM)

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) issued its earnings results on Tuesday, August, 8th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.02. View Verastem's Earnings History.

When will Verastem make its next earnings announcement?

Verastem is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Verastem.

Where is Verastem's stock going? Where will Verastem's stock price be in 2017?

6 equities research analysts have issued 1 year price targets for Verastem's shares. Their predictions range from $1.50 to $17.00. On average, they expect Verastem's share price to reach $7.75 in the next twelve months. View Analyst Ratings for Verastem.

What are analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:

  • 1. Cantor Fitzgerald analysts commented, "VSTM has made a $6 million milestone payment to INFI (Not Covered), following positive Phase III DUO results in September, with a final milestone of $22 million due upon regulatory approval, which could come in 2019 following a 2018 NDA filing." (10/17/2017)
  • 2. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (8/12/2017)
  • 3. Cann analysts commented, "Verastem announced today that scientific findings from two studies evaluating focal adhesion kinase (FAK) inhibition in preclinical models of pancreatic and breast cancer with the publication of two papers in the peer-reviewed journals PLoS One and Oncotarget. The company reported that these two published articles continue to validate its underlying thesis for ongoing clinical collaborations evaluating lead FAK inhibitor defactinib in combination with chemotherapeutic and leading immunotherapeutic agents in several difficult-to-treat cancers." (7/25/2017)
  • 4. HC Wainwright analysts commented, "According to management, the topline results from the Phase 3 DUO study of duvelisib (a PI3K-??/PI3K-?? inhibitor) for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) are expected around mid-year 2017. Recall, DUO is a 300-patient, randomized, controlled study comparing the use of duvelisib monotherapy to ofatumumab, an anti-CD20 antibody marketed as Arzerra by Novartis (NVS; not rated), for the treatment of CLL, with the primary endpoint of progression-free survival (PFS) and secondary endpoints that include overall response rate (ORR) and overall survival (OS). Based on results from earlier stage studies in CLL as well as the previously completed DYNAMO study in indolent non-Hodgkin's lymphoma (iNHL), we believe that DUO is highly likely to meet its primary PFS endpoint. Furthermore, while many investors have doubts regarding duvelisib's commercial outlook in the competitive CLL indication, we believe that, even with less-than-stellar results from DUO, the drug has the potential to capture a material portion of the highly lucrative market for 2nd/3rd-line CLL treatments. Therefore, we expect positive results from the DUO study to be a significant catalyst for the company. Based on our analysis of duvelisib's commercial potential, we are increasing our price target to $6.50 per diluted share, up from $5.00." (3/24/2017)

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:

  • Robert Forrester, President, Chief Executive Officer
  • Julie B. Feder, Chief Financial Officer
  • Daniel W. Paterson, Chief Operating Officer
  • Joseph Chiapponi, Vice President - Finance
  • Monica Kleinman, Vice President, General Counsel
  • Michael Ferraresso, Vice President - Commercial Operations
  • Lori A. Kunkel M.D., Clinical and Scientific Advisory Board
  • Hagop Youssoufian M.Sc., M.D.,, Head - Hematology and Oncology Development
  • Michael G. Kauffman M.D. Ph.D., Lead Independent Director
  • Eric K. Rowinsky M.D., Director

How do I buy Verastem stock?

Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of Verastem stock can currently be purchased for approximately $3.95.

MarketBeat Community Rating for Verastem (NASDAQ VSTM)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Verastem (NASDAQ:VSTM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $7.75 (96.20% upside)
Consensus Price Target History for Verastem (NASDAQ:VSTM)
Price Target History for Verastem (NASDAQ:VSTM)
Analysts' Ratings History for Verastem (NASDAQ:VSTM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Cantor FitzgeraldSet Price TargetBuy$17.00N/AView Rating Details
10/12/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$6.00N/AView Rating Details
9/7/2017HC WainwrightReiterated RatingBuy -> Buy$6.50 -> $10.00LowView Rating Details
8/16/2017CannReiterated RatingBuyLowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingHold$1.50HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> Outperform$6.00HighView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Verastem (NASDAQ:VSTM)
Earnings by Quarter for Verastem (NASDAQ:VSTM)
Earnings History by Quarter for Verastem (NASDAQ VSTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.32)N/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.36)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.35)($0.35)ViewN/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Verastem (NASDAQ:VSTM)
2017 EPS Consensus Estimate: ($1.40)
2018 EPS Consensus Estimate: ($2.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.36)($0.36)($0.36)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.32)($0.32)($0.32)
Q1 20181($0.42)($0.42)($0.42)
Q2 20181($0.48)($0.48)($0.48)
Q3 20181($0.56)($0.56)($0.56)
Q4 20181($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)


Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Verastem (NASDAQ:VSTM)
Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 24.19%
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Timothy J BarberichDirectorBuy30,000$2.45$73,500.00View SEC Filing  
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Verastem (NASDAQ:VSTM)
Latest Headlines for Verastem (NASDAQ:VSTM)
DateHeadline logoVerastem Pays Milestone Payment to Infinity Pharmaceuticals - Business Wire (press release) - October 17 at 8:56 AM logoVerastem Pays Milestone Payment to Infinity Pharmaceuticals - October 17 at 8:56 AM logoVerastem, Inc. (VSTM) Rating Reiterated by Oppenheimer Holdings, Inc. - October 12 at 2:34 PM logoVerastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer - October 12 at 10:00 AM logoZacks: Brokerages Expect Verastem, Inc. (VSTM) to Post -$0.32 Earnings Per Share - October 9 at 6:12 AM logoVerastem, Inc. (VSTM) Receives Average Rating of "Hold" from Analysts - October 8 at 6:50 AM logoVerastem to Present at the Cantor Fitzgerald Global Healthcare Conference - September 23 at 10:52 AM logoVerastem to Present at the Cantor Fitzgerald Global Healthcare Conference - September 23 at 10:52 AM logo-$0.32 Earnings Per Share Expected for Verastem, Inc. (VSTM) This Quarter - September 20 at 4:12 PM logoShort Interest in Verastem, Inc. (VSTM) Grows By 92.9% - September 16 at 1:20 AM logoVerastem, Inc. (VSTM) Receives Average Recommendation of "Hold" from Analysts - September 13 at 8:04 AM logoVerastem, Inc. (VSTM) Stock Rating Reaffirmed by HC Wainwright - September 7 at 11:01 AM logoVerastem Boosted After Positive Top-Line Data For Leukemia Treatment - September 7 at 10:58 AM logoToday's Research Reports on Stocks to Watch: Moleculin Biotech and Verastem - September 7 at 10:58 AM logoOppenheimer Holdings, Inc. Reaffirms Buy Rating for Verastem, Inc. (VSTM) - September 6 at 3:56 PM logoVerastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - September 6 at 10:02 AM logoCantor Fitzgerald Upgrades Verastem, Inc. (VSTM) to "Overweight" - September 6 at 9:33 AM logoVerastem, Inc. (VSTM) Short Interest Down 48.9% in August - August 28 at 1:20 AM logoImplied Volatility Surging for Verastem (VSTM) Stock Options - August 19 at 8:54 AM logoVerastem, Inc. (VSTM) Given Consensus Rating of "Hold" by Analysts - August 19 at 6:50 AM logoVerastem's (VSTM) "Buy" Rating Reaffirmed at Cann - August 16 at 8:26 PM logoVerastem, Inc. (NASDAQ:VSTM) Expected to Announce Earnings of -$0.32 Per Share - August 14 at 2:30 PM logoVerastem, Inc. (NASDAQ:VSTM) Sees Large Growth in Short Interest - August 13 at 1:46 AM logoVerastem, Inc. to Post Q3 2017 Earnings of ($0.35) Per Share, Oppenheimer Holdings Forecasts (VSTM) - August 11 at 7:48 AM logoVerastem, Inc. (NASDAQ:VSTM) Announces Quarterly Earnings Results - August 9 at 2:35 PM logoVerastem Reports Second Quarter 2017 Financial Results - Business Wire (press release) - August 9 at 8:59 AM logoVerastem Reports Second Quarter 2017 Financial Results - August 9 at 8:59 AM logoVerastem, Inc. (NASDAQ:VSTM) Scheduled to Post Earnings on Monday - July 31 at 8:16 AM logoVerastem, Inc. (NASDAQ:VSTM) Expected to Post Earnings of -$0.34 Per Share - July 27 at 10:35 AM logoVerastem Shows Long-Term Potential With Strong DYNAMO Data - Seeking Alpha - July 26 at 9:52 AM logoVerastem, Inc. (VSTM) Given Consensus Recommendation of "Buy" by Brokerages - July 25 at 8:43 AM logoVerastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer - Business Wire (press release) - July 25 at 8:19 AM logoVerastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer - July 25 at 8:19 AM logoExclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock - Benzinga - July 18 at 9:51 AM logoVerastem continues up move, shares ahead 20% - July 11 at 2:46 PM logoCompany Spotlight: Verastem - Nasdaq - July 8 at 9:52 PM logoGainers & Losers Of July 6: VSTM, BGNE, ALRN, TXMD, OCUL... - July 8 at 4:50 PM logoVerastem (VSTM) Shows Strength: Stock Adds 42% in Session - July 8 at 4:50 PM logo-$0.34 Earnings Per Share Expected for Verastem Inc (NASDAQ:VSTM) This Quarter - July 3 at 8:35 AM logoVerastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib - Quick Facts - June 25 at 11:05 PM logoVerastem (VSTM) Present Long-Term Follow-Up Data from the DYNAMO Study at ICML - June 8 at 1:56 AM logoVerastem (VSTM) Announces Duvelisib Data Presentations at EHA - - May 19 at 1:39 PM logoVerastem (VSTM) Announces Duvelisib Data Presentations at EHA - May 18 at 10:07 AM logoVerastem (VSTM) Announces Long Term Follow-up Data from DYNAMO Study to be Presented at ICML - May 3 at 11:55 PM logoVERASTEM, INC. Files SEC form 10-K, Annual Report - March 23 at 8:54 PM logoVerastem Inc Earnings Call scheduled for 4:30 pm ET today - March 23 at 8:54 PM logoInfinity Pharma Surges On Latest Cancer Drug Hope - January 25 at 4:25 PM logoVerastem Announces Executive Leadership Appointments and ... - Business Wire (press release) - January 20 at 6:03 AM logoVerastem Announces Executive Leadership Appointments and Changes - January 19 at 9:03 PM logo4:30 pm Verastem appoints Hagop Youssoufian as Head of Hematology and Oncology Development - January 19 at 9:03 PM



Verastem (VSTM) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.